Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Ipilimumab and Camrelizumab in NSCLC
NCT03527251Phase 1Unknown
- Sponsor
- Sun Yat-sen University
- Start
- May 2018
- Primary completion
- Dec 2018
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of camrelizumab in non-small cell lung cancer (NSCLC), sponsored by Sun Yat-sen University. Primary endpoint: Safety in the treatment of ipilimumab followed by SHR1210 at 24 months. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03527251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03527251.